Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

52.95 -0.32 (-0.60%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
31 32 Next >
This Monster Dividend Stock Isn't Done Growing
Is another deal on the way for Johnson & Johnson? 
Via The Motley Fool
Revolution Medicines Regains Global Rights To Mid-Stage Cancer Program As Sanofi Terminates Collaboration
Via Benzinga
Fusion Fuel (HTOO) Stock Is Up 11% on HUGE Deal News
Fusion Fuel (HTOO) stock is heading higher on Wednesday after the company secured a deal with the Portuguese government. 
Via InvestorPlace
Why Is TransCode Therapeutics (RNAZ) Stock Up 148% Today?
TransCode Therapeutics (RNAZ) stock is rallying higher on Wednesday after the company withdrew plans for a secondary offering. 
Via InvestorPlace
SNY Stock Alert: Why 1 Analyst Says Zantac Ruling Is ‘Best-Case Scenario’ for Drugmakers
Sanofi (SNY) stock is in the news as one analyst believes the latest court ruling is the "best-case scenario" for the drugmaker. 
Via InvestorPlace
Europe Approves Sanofi's Enjaymo For Rare Form Of Anemia
Via Benzinga
Meta Criticized For Providing Extra Protection To Certain Users, Twitter HQ Bedrooms Under Regulatory Scrutiny, Juul Settles Over 5,000 Lawsuits: Top Stories Wednesday, Dec. 07
Benzinga 
Via Benzinga
Relief To Pfizer, Sanofi As US Dismisses Several Lawsuits Associated With Zantac
Via Benzinga
These 3 Stocks Escaped Tuesday's Market Downdraft
Even a dour outlook for the broader stock market couldn't outweigh good news for these companies. 
Via The Motley Fool
Why GSK Plc And Sanofi SA Stock Are Shooting Higher
Shares of GSK plc (NYSE: GSK) and Sanofi SA (NASDAQ: SNY) are trading higher going into the close of Tuesday's session after the companies reportedly won a Zantac product liability lawsuit. 
Via Benzinga
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
From Singapore Economic Development Board (EDB)A*STAR
Via ACN Newswire
Horizon Topples After J&J Pulls Out Of Bidding War, Leaving Amgen, Sanofi
There are now two companies in the ring for a Horizon takeover. 
Via Investor's Business Daily
Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review
The S&P 500 is fighting for its 200-day, a critical level for the uptrend. 
Via Investor's Business Daily
If Sanofi Opted For Takeover Of Horizon Therapeutics, It Would Be In Cash
Via Benzinga
Why Horizon Therapeutics Stock Is Skyrocketing Today
Three big drugmakers could be interested in acquiring Horizon. 
Via The Motley Fool
Why Is Horizon Therapeutics (HZNP) Stock Up 30% Today?
Horizon Therapeutics (HZNP) stock is rising higher on Wednesday following reports that the company is considering a buyout. 
Via InvestorPlace
Are Tech Layoffs Going to Be a Headache for Alexandria Real Estate Equities?
Tech layoffs are in the news, but life sciences companies seem to be doing better. 
Via The Motley Fool
UK Drug Regulator Warns Of Severe Eye Reactions Associated With Sanofi/Regeneron's Dupixent
Via Benzinga
iPhone Pro Shipments May Miss Consensus, Tesla Rival Charts Ambitious Expansion Plan In Mexico, Amazon Cloud Unit To Add More Employees: Top Stories Wednesday, Nov. 30
Reuters 
Via Benzinga
Horizon Therapeutics Shares Jump On Confirmation Of Takeover Talks With Several Large Companies
Via Benzinga
Horizon Therapeutics Rockets As It Considers Potential Bids From Amgen, J&J, Sanofi
The three companies have until Jan. 10 to decide whether they want to buy Horizon. 
Via Investor's Business Daily
First Drug That Can Delay Onset of Type 1 Diabetes Gets FDA Approval After Multiple Regulatory Hurdles
Via Benzinga
Daily Stock Analysis: Sanofi - November 2022 Snapshot
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. The company's decided in late 2019 to pull back from the cardio-metabolic... 
Via Talk Markets
A Paradigm Shift In Healthcare Produces A Big Market Opportunity
In a couple of years, Dario Heath could easily be a $100M+ company running 60%+ gross margins, be profitable and cash generating. 
Via Talk Markets
Eli Lilly's Twitter Fiasco Continues As Drugmaker Reportedly Pulls 'Millions' In Twitter Ads
The fallout from a fake account continued Monday as Lilly reportedly pulled Twitter ads. 
Via Investor's Business Daily
Can This Company's Research Help Transform Regenerative Medicine As Its Lead Product Receives FDA IND Approval?
Learn More about Organicell Regenerative Medicine, Inc. by gaining access to the latest research report In the medical community, the popularity of regenerative medicine is reportedly soaring primarily... 
Via Benzinga
Week In Review: Insilico Signs Six-Drug Discovery Deal With Sanofi Worth Up To $1.2 Billion
Insilico Medicine signed a six-drug research collaboration with Sanofi that could be worth up to $1.2 billion. Insilico will receive up to $21.5 million in upfront and target nomination fees for each... 
Via Talk Markets
2 Top Biotech Stocks to Buy in November
Both of these companies have potential catalysts on the way. 
Via The Motley Fool
Eli Lilly Dives After Fake Twitter Account Promises Free Insulin; Takes Novo Nordisk, Sanofi With It
A fake, but verified, Twitter account impersonated Eli Lilly and claimed insulin is free. 
Via Investor's Business Daily
Europe Approves Sanofi, GSK's Beta Variant Adapted COVID Shot As Booster
Via Benzinga
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.